Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.57 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2166377 | 0.86 | ALOX5 (0.65) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| SCHEMBL1066614 | 0.86 | FFAR1 (0.70) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| SCHEMBL4222632 | 0.84 | FFAR1 (0.68) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| Hydrochloric Acid SCHEMBL10622121 | 0.84 | FFAR1 (0.68) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| Ammonia Solution, Strong SCHEMBL27788257 | 0.84 | FFAR1 (0.68) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| SCHEMBL6156467 | 0.83 | ALOX5 (0.65) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| SCHEMBL224149 | 0.83 | ALOX5 (0.65) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| SCHEMBL68570 | 0.83 | ALOX5 (0.69) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| SCHEMBL1395785 | 0.83 | PARP10 (0.68) | ALOX5NR4A1NR4A2NR4A3FFAR1 | |
| SCHEMBL20867886 | 0.81 | ALDH1A1 (0.77) | ALOX5NR4A1NR4A2NR4A3FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572795-B2 | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090156555-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-18 | — | — | US | disclosed |
| CN-101395158-A | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-03-25 | — | — | CN | disclosed |
| EP-2001886-A2 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007103839-A2 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213300-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156555-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | CDK2, CDK3, CDK1 | ALOX5 4215/4885NR4A1 2433/4885NR4A2 2218/4885 |
| US-20070213300-A1 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS | CDK2, CDK3, CDK1 | ALOX5 4170/4885NR4A1 2402/4885NR4A2 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.